SCHAUMBURG, Ill., June 30, 2011 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT) today announced U.S. FDA approval of polymyxin B for injection, USP, an antibacterial drug, in 500,000 units per vial, latex-free glass vials. According to 2010 IMS data, the U.S. market for injectable polymyxin B approximated $8 million. As with all products in Sagent’s portfolio, polymyxin B features the company’s PreventIV Measures packaging and labeling designed to aid in the reduction of medication errors.
